Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 6/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 5/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.79 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | SHBG | P04278 | 3/20 | 0.79 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.79 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.79 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.79 |
| ▸ | THPO | P40225 | 2/20 | 0.79 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.79 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 11Beta-Hydroxyprogesterone SCHEMBL18927076 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL14217113 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL985222 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL23131395 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL656895 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL24900301 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL19327159 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL13753022 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL4895684 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 | |
| 11Beta-Hydroxyprogesterone SCHEMBL14039977 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2NR3C2HSD11B2HSD11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | claimed |
| US-20250017895-A1 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-01-16 | — | — | US | claimed |
| CN-114836387-B | 11-alpha hydroxyprogesterone monoclonal antibody hybridoma cell strain and application thereof | 江南大学 | 2023-08-04 | — | — | CN | claimed |
| WO-2023097328-A2 | FLAVANOID CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2023-06-01 | — | — | WO | claimed |
| CN-115607510-A | High-concentration oleanolic acid nanoemulsion composition and preparation method thereof | 泉州达浔生物科技有限公司 | 2023-01-17 | — | — | CN | claimed |
| US-11207511-B2 | Methods for treating baldness and promoting hair growth | FOLLICA, INC. (US) | 2021-12-28 | — | — | US | claimed |
| CN-109517020-A | The synthetic method of Delta-9,11- hydroxyl progesterone | 湖南原野医药有限公司 | 2019-03-26 | — | — | CN | claimed |
| US-20140079686-A1 | Methods For Treating Baldness And Promoting Hair Growth | FOLLICA, INC. | 2014-03-20 | — | — | US | claimed |
| US-8470602-B2 | Methods and systems for determining the presence or amount of delta 5 steroid compounds in a sample | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2013-06-25 | — | — | US | claimed |
| US-20120270327-A1 | Methods and Systems for Determining the Presence or Amount of Delta 5 Steroid Compounds in a Sample | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2012-10-25 | — | — | US | claimed |
| EP-1473300-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER SKIN DISEASES | LITAPHAR LAB S A (ES) | 2008-11-26 | — | — | EP | claimed |
| EP-1613357-B1 | GONADOTROPIN RELEASING HORMONE ANALOGUE CONJUGATES WITH STEROID HORMONES | MEDICAL RES COUNCIL (GB) | 2008-10-15 | — | — | EP | claimed |
| US-20060099643-A1 | Method for determining the regulation of xenobiotic removal | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT LLC | 2006-05-11 | — | — | US | claimed |
| US-20040225140-A1 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases | FERNANDEZ PIDAL (ES) | 2004-11-11 | — | — | US | claimed |
| EP-1473300-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER SKIN DISEASES | Litaphar Laboratorios S.A. (ES) | 2004-11-03 | — | — | EP | claimed |
| US-5968918-A | Method for the prevention of coronary artery spasm | KANDA IWAO (US) | 1999-10-19 | — | — | US | claimed |
| US-4885289-A | APPLYING ANTIANDROGEN TO SKIN | GILLETTE COMPANY | 1989-12-05 | — | — | US | claimed |
| EP-0141684-B1 | HYDROCORTISONE-17-CARBOXYLIC-ACID ESTER 21-THIOCARBOXYLYC-ACID ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINES | JOUVEINAL S.A. (FR) | 1987-09-30 | — | — | EP | claimed |
| EP-0054390-B1 | DEHALOGENATION OF STEROIDS | THE UPJOHN COMPANY (US) | 1984-07-25 | — | — | EP | claimed |
| US-4272508-A | TREATMENT WITH 11-2-HYDROXYPROGESTERONE AND ESTERS THEREOF | TAMM JURGEN | 1981-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079686-A1 | Methods For Treating Baldness And Promoting Hair Growth | AREG, FGF1, NGF | SMN1; SMN2 4725/4885NR3C2 376/4885HSD11B2 266/4885 |
| US-11207511-B2 | Methods for treating baldness and promoting hair growth | AREG, FGF1, NGF | SMN1; SMN2 4725/4885NR3C2 376/4885HSD11B2 266/4885 |
| US-20040225140-A1 | Pharmaceutical composition for the treatment of psoriasis and other skin diseases | HSD17B7, HSD17B1, CYP17A1 | SMN1; SMN2 3856/4885NR3C2 27/4885HSD11B2 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.